HK11191A - Analogs of mevalolactone and derivatives thereof,processes for their production,pharmaceutical compositions containing them and their use as pharmaceuticals - Google Patents

Analogs of mevalolactone and derivatives thereof,processes for their production,pharmaceutical compositions containing them and their use as pharmaceuticals

Info

Publication number
HK11191A
HK11191A HK111/91A HK11191A HK11191A HK 11191 A HK11191 A HK 11191A HK 111/91 A HK111/91 A HK 111/91A HK 11191 A HK11191 A HK 11191A HK 11191 A HK11191 A HK 11191A
Authority
HK
Hong Kong
Prior art keywords
hydrogen
benzyloxy
phenoxy
trifluoromethyl
fluoro
Prior art date
Application number
HK111/91A
Other languages
English (en)
Inventor
Faizulla Gulamhusein Kathawala
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of HK11191A publication Critical patent/HK11191A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK111/91A 1982-11-22 1991-02-06 Analogs of mevalolactone and derivatives thereof,processes for their production,pharmaceutical compositions containing them and their use as pharmaceuticals HK11191A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44366882A 1982-11-22 1982-11-22
US54885083A 1983-11-04 1983-11-04

Publications (1)

Publication Number Publication Date
HK11191A true HK11191A (en) 1991-02-13

Family

ID=27033614

Family Applications (1)

Application Number Title Priority Date Filing Date
HK111/91A HK11191A (en) 1982-11-22 1991-02-06 Analogs of mevalolactone and derivatives thereof,processes for their production,pharmaceutical compositions containing them and their use as pharmaceuticals

Country Status (18)

Country Link
EP (1) EP0114027B1 (fi)
JP (1) JPH0347167A (fi)
AT (1) ATE31718T1 (fi)
AU (1) AU570021B2 (fi)
CA (1) CA1210405A (fi)
CY (1) CY1579A (fi)
DE (2) DE19475017I2 (fi)
DK (2) DK359284D0 (fi)
FI (1) FI77228C (fi)
GR (1) GR79042B (fi)
HK (1) HK11191A (fi)
HU (1) HU204253B (fi)
IE (1) IE56262B1 (fi)
IL (1) IL70286A (fi)
LU (1) LU88670I2 (fi)
NL (1) NL950022I2 (fi)
NZ (1) NZ206338A (fi)
WO (1) WO1984002131A1 (fi)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
KR910003427B1 (ko) * 1984-12-04 1991-05-31 산도즈 파마슈티칼스 코포레이션 메발로노락톤의 인덴동족체 및 이들의 유도체의 제법
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
HUT48208A (en) * 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
PT85662B (pt) * 1986-09-10 1990-06-29 Sandoz Sa Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US4904646A (en) * 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
HU202842B (en) * 1988-01-27 1991-04-29 May & Baker Ltd Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
JP2853227B2 (ja) * 1988-10-13 1999-02-03 ノバルテイス・アクチエンゲゼルシヤフト ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法
JPH04270285A (ja) * 1988-11-14 1992-09-25 Nissan Chem Ind Ltd ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) * 1989-08-22 1989-10-04 Fujisawa Pharmaceutical Co Pyrroloquinoline compounds
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
JP2736599B2 (ja) * 1993-07-23 1998-04-02 株式会社キッツ ボールバルブのシート構造
US6425881B1 (en) 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
EP0988289A2 (en) 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
JP4809533B2 (ja) 1998-11-20 2011-11-09 オバン・エナジー・リミテッド 分散し得るリン脂質で安定化されたミクロ粒子
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6743926B2 (en) 2000-05-26 2004-06-01 Ciba Specialty Chemicals Corporation Process for the preparation of indole derivatives and intermediates of the process
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
BR0209124A (pt) 2001-04-18 2005-02-09 Genzyme Corp Método para tratar uma sìndrome x ou inibir o inìcio dos sintomas da sìndrome x e uso de uma quantidade terapeuticamente efetiva de um sal de pelo menos um polìmero de amina alifática
ES2304140T3 (es) * 2001-08-03 2008-09-16 Ciba Holding Inc. Formas cristalinas de sodio de fluvastatina.
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US20050239815A1 (en) 2002-04-12 2005-10-27 Kim Annette J Tyrosine kinase inhibitors
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) * 2003-08-27 2008-07-23 住友化学株式会社 芳族不饱和化合物的制备方法
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
KR20070085874A (ko) 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
WO2007046842A2 (en) 2005-03-02 2007-04-26 Merck & Co., Inc. Composition for inhibition of cathepsin k
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
US8354530B2 (en) 2005-07-28 2013-01-15 Lek Pharmaceuticals d. d Process for the synthesis of rosuvastatin calcium
WO2007059372A2 (en) 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
JP5328640B2 (ja) 2006-04-19 2013-10-30 ノバルティス アーゲー ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
ES2327668T3 (es) 2006-04-20 2009-11-02 F.I.S. Fabbrica Italiana Sintetici S.P.A. Procedimiento para la preparacion de sal sodica de fluvastatina.
CN102764440A (zh) 2006-07-05 2012-11-07 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CA2761934C (en) 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2797641B1 (en) 2011-12-29 2019-07-10 Trustees Of Tufts College Functionalization of biomaterials to control regeneration and inflammation responses
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
EP2968275B1 (en) 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
EP3055314B1 (en) 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Also Published As

Publication number Publication date
IL70286A0 (en) 1984-02-29
NL950022I1 (fi) 1996-01-02
GR79042B (fi) 1984-10-02
DK359284A (da) 1984-07-20
CA1210405A (en) 1986-08-26
DK165244C (da) 1993-03-22
FI842615A0 (fi) 1984-06-28
DK97890A (da) 1990-04-19
DK97890D0 (da) 1990-04-19
AU570021B2 (en) 1988-03-03
HU204253B (en) 1991-12-30
IE56262B1 (en) 1991-06-05
JPH0347167A (ja) 1991-02-28
LU88670I2 (fr) 1996-04-29
FI77228B (fi) 1988-10-31
IE832713L (en) 1984-05-22
IL70286A (en) 1987-08-31
DE3375137D1 (en) 1988-02-11
EP0114027B1 (en) 1988-01-07
ATE31718T1 (de) 1988-01-15
DK165244B (da) 1992-10-26
DK359284D0 (da) 1984-07-20
AU2261283A (en) 1984-06-18
NL950022I2 (nl) 1996-12-02
FI77228C (fi) 1989-02-10
JPH0440343B2 (fi) 1992-07-02
DE19475017I2 (de) 2003-02-20
WO1984002131A1 (en) 1984-06-07
NZ206338A (en) 1987-08-31
CY1579A (en) 1991-12-20
EP0114027A1 (en) 1984-07-25
FI842615A (fi) 1984-06-28
HUT35642A (en) 1985-07-29

Similar Documents

Publication Publication Date Title
DE3375137D1 (en) Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
AU4541689A (en) Quinazolinonederivatives which are bronchodilators and vasodilators
DE3278501D1 (en) Antiviral compounds
AU570942B2 (en) Analogs of mevalonolactone and derivatives thereof, processesfor their production, pharmaceutical compositions containing them and their use as pharmaceuticals
ES8306371A1 (es) "un procedimiento para la preparacion de sales de s-adenosilmetionina".
EP0228845A3 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
DE3362260D1 (en) (-)-15-deoxyspergualin, a process for the preparation of the same, and a pharmaceutical composition containing the same

Legal Events

Date Code Title Description
PE Patent expired